IP Library Granted Patent US 10,820,977
Granted Patent B2
US 10,820,977 · App. 15/660,817 · Granted Nov 3, 2020

Method and apparatus for administering supplemental oxygen therapy at ambient conditions using a veterinary hyperbaric chamber

Inventors: Deepak Ambalal Talati (Yorba Linda, CA); Danny Bruce Hudson (Perris, CA); Teofilo Raymund G. Tan, III (Anaheim, CA); Ronald Lyman (Fort Pierce, FL)
Assignee: Sechrist Industries, Inc.
A61D7/00A61D7/04A61G10/026A62B31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,820,977
App. No.
15/660,817
Granted
Nov 3, 2020
Kind
B2
Abstract

A system and method of administrating conventional hyperbaric chamber therapy as well as supplemental oxygen therapy at ambient conditions to an animal using a veterinary hyperbaric chamber. The hyperbaric chamber can function in its usual mode of operation; i.e., providing oxygen at greater than atmospheric pressure and also in a second mode of operation to administer supplemental oxygen thereafter at ambient pressure conditions. In the second mode of operation, the method and apparatus may deliver approximately 80 liters per minute continuous flow of 0.21 through 1.0 FI02 adjustable oxygen gas mixture. The mixture is delivered at ambient pressure from one end of the chamber, flows across the animal positioned within the hyperbaric chamber, and exits at the opposite end for exhaust to ambient conditions. A high flow gas mixture is utilized to maintain accurate gas mixture concentrations with fluctuating supply pressures of medical air and medical oxygen gases.

Claims (56)

1. A multi-mode, veterinary therapy chamber device comprising:

a housing including a therapy chamber;

an oxygen inlet connectable to a source of pressurized oxygen;

an air inlet connectable to a source of pressurized air;

a master control valve connectable to the oxygen inlet to receive pressurized oxygen therefrom, the master control valve being transitional between at least a first position and a second position; and

a fluid delivery network connected to the master control valve and the therapy chamber, the fluid delivery network having a first passageway and a second passageway both of which extend from the master control valve so as to receive fluid from the master control valve;

when the master control valve is in the first position, the first passageway is in fluid communication with the oxygen inlet and is fluidly isolated from the air inlet, and the second passageway is fluidly isolated from both the oxygen inlet and air inlet to facilitate delivery of oxygen to the therapy chamber along the first passageway;

when the master control valve is in the second position, the first passageway is fluidly isolated from both the oxygen inlet and the air inlet, and the second passageway is in fluid communication with the oxygen inlet and the air inlet to facilitate a mixture of oxygen and air to the therapy chamber alone the second passageway.

2. The device recited in claim 1 , wherein the fluid delivery network includes a mixer fluidly connectable to the oxygen inlet and the air inlet when the fluid delivery network is in the second operational mode, the mixer being operative to facilitate varying a ratio of oxygen-to-air in the mixture delivered to the therapy chamber.

3. The device recited in claim 2 , wherein the mixer includes:

a mixer air inlet;

a mixer oxygen inlet;

a pressure balancing chamber in communication with the mixer air inlet and the mixer oxygen inlet;

a diaphragm extending through the pressure balancing chamber;

an air valve body coupled to the diaphragm, the air valve body being sized and positioned to control fluid flow from the mixer air inlet to the pressure balancing chamber; and

an oxygen valve body coupled to the diaphragm, the oxygen valve body being sized and positioned to control fluid flow from the mixer oxygen inlet to the pressure balancing chamber.

4. The device recited in claim 3 , wherein the mixer further includes:

a mixing chamber in communication with the pressure balancing chamber; and

a valve body moveable relative to the mixing chamber, the valve body being sized and structured to vary the ratio of oxygen-to-air in the mixture exiting the mixing chamber for delivery to the therapy chamber.

5. The device recited in claim 4 , wherein the mixer includes a mixer housing and the valve body includes at least one tapered surface which interfaces with the mixer housing for varying the ratio of oxygen-to-air in the mixture exiting the mixing chamber for delivery to the therapy chamber.

6. The device recited in claim 3 , wherein the mixer further includes an alarm in fluid communication with the mixer air inlet and the mixer oxygen inlet, the alarm generating an alarm signal in response to fluid pressure at one of the mixer air inlet and the mixer oxygen inlet falling below a prescribed threshold.

7. The device recited in claim 2 , wherein the fluid delivery network includes:

a first oxygen valve in fluid communication with the oxygen inlet;

a second oxygen valve in fluid communication with the oxygen inlet and the mixer; and

an air valve in fluid communication with the air inlet and the mixer;

in the first operational mode, the first oxygen valve being open to allow pressurized oxygen to flow therethrough, and the second oxygen valve and air valve both being closed to prevent fluid flow therethrough;

in the second operational mode, the first oxygen valve being closed to prevent fluid flow therethrough, and the second oxygen valve and air valve both being open to allow pressurized oxygen and pressurized air to flow through the second oxygen valve and the air valve, respectively.

8. The device recited in claim 7 , wherein the first oxygen valve, second oxygen valve, and air valve are normally closed, and are capable of being transitioned to respective open positions in response to a pressurized control fluid being applied thereto.

9. The device recited in claim 1 , further comprising a fluid control passageway extending between the master control valve and at least one of the oxygen inlet and the air inlet.

10. The device recited in claim 1 , wherein the fluid delivery network includes an alarm operative to generate an alarm signal in response to a fluid pressure within the fluid delivery network falling below a prescribed threshold.

11. The device recited in claim 1 , further comprising a relief valve in communication with the fluid delivery network, the relief valve being operative to exhaust fluid from the fluid delivery network in response to a fluid pressure in the fluid delivery network exceeding a prescribed threshold.

12. The device recited in claim 11 , wherein the prescribed threshold is 35 PSI.

13. The device recited in claim 1 , further comprising a vent valve downstream of the therapy chamber, the vent valve being normally closed and operative to open to vent fluid from the therapy chamber.

14. A multi-mode, veterinary therapy chamber device comprising:

a housing including a therapy chamber;

an oxygen inlet connectable to a source of pressurized oxygen;

an air inlet connectable to a source of pressurized air;

a control conduit in communication with the oxygen inlet to receive pressurized oxygen therefrom;

a master control valve in communication with the control conduit to receive pressurized oxygen therefrom, the master control valve being transitional between at least a first position and a second position;

a first passageway and a second passageway both fluidly connected to the master control valve and the therapy chamber;

when the master control valve is in the first position, the master control valve directs pressurized oxygen from the control conduit to the first passageway and the first passageway is fluidly isolated from the air inlet to facilitate delivery of oxygen to the therapy chamber along the first passageway, and the second passageway is fluidly isolated from both the oxygen inlet and air inlet;

when the master control valve is in the second position, the master control valve directs pressurized oxygen from the control conduit to the second passageway, and the second passageway receives pressurized air from the air inlet to facilitate delivery of a mixture of pressurized oxygen and air to the therapy chamber, and the first passageway is fluidly isolated from both the oxygen inlet and the air inlet.

15. The device recited in claim 14 , further comprising a normally closed oxygen valve that is pneumatically actuated from a closed position to an open position in response to the master control valve assuming its second position.

16. The device recited in claim 15 , further comprising a normally closed air valve that is pneumatically actuated from a closed position to an open position in response to the master control valve assuming its second position.

17. The device recited in claim 16 , further comprising a mixer disposable in communication with the air inlet and the oxygen inlet and downstream of both the oxygen valve and the air valve to receive pressurized air and pressurized oxygen from the air inlet and the oxygen inlet when the master control valve assumes its second position.

18. The device recited in claim 17 , wherein the mixer includes:

a mixer air inlet;

a mixer oxygen inlet;

a pressure balancing chamber in communication with the mixer air inlet and the mixer oxygen inlet;

a diaphragm extending through the pressure balancing chamber;

an air valve body coupled to the diaphragm, the air valve body being sized and positioned to control fluid flow from the mixer air inlet to the pressure balancing chamber; and

an oxygen valve body coupled to the diaphragm, the oxygen valve body being sized and positioned to control fluid flow from the mixer oxygen inlet to the pressure balancing chamber.

19. The device recited in claim 18 , wherein the mixer further includes:

a mixing chamber in communication with the pressure balancing chamber; and

a valve body moveable relative to the mixing chamber, the valve body being sized and structured to vary the ratio of oxygen-to-air in the mixture exiting the mixing chamber for delivery to the therapy chamber.

20. The device recited in claim 19 , wherein the mixer includes a mixer housing and the valve body includes at least one tapered surface which interfaces with the mixer housing for varying the ratio of oxygen-to-air in the mixture exiting the mixing chamber for delivery to the therapy chamber.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded May 13, 2021
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: SECHRIST INDUSTRIES, INC.
Reel/Frame 056241/0383 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded May 13, 2021
From: JPMORGAN CHASE BANK, N.A.
To: SECHRIST INDUSTRIES, INC.
Reel/Frame 056241/0421 →
PATENT SECURITY AGREEMENT Recorded May 13, 2021
From: SECHRIST INDUSTRIES, INC.
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 056240/0300 →
NOTICE OF AGENCY RESIGNATION AND ASSIGNMENT OF PATENT SECURITY AGREEMENT Recorded Jan 26, 2021
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, RESIGNING COLLATERAL AGENT
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, SUCCESSOR COLLATERAL AGENT
Reel/Frame 055125/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE DOCUMENT SUBMISSION TO ADD GRANTOR SIGNATURE PAGE. PREVIOUSLY RECORDED AT REEL: 050454 FRAME: 0417. ASSIGNOR(S) HEREBY CONFIRMS THE SECOND LIEN PATENT SECURITY AGREEMENT.. Recorded Oct 15, 2019
From: SECHRIST INDUSTRIES, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 050728/0025 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Sep 10, 2019
From: SECHRIST INDUSTRIES, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 050454/0417 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Apr 25, 2018
From: SECHRIST INDUSTRIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 046019/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2017
From: TALATI, DEEPAK AMBALAL; HUDSON, DANNY BRUCE; TAN, TEOFILO RAYMUND G., III; LYMAN, RONALD
To: SECHRIST INDUSTRIES, INC.
Reel/Frame 043229/0796 →
Continuity (3)
Provisional Application 62369656 · Aug 1, 2016
Provisional Application 62399681 · Sep 26, 2016
Related Publication 20180028299A1 · Feb 1, 2018